MRNA vs SYRE โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
MRNA Captures Institutional Edge (3โ1 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Moderna, Inc. Common Stock (MRNA) driven by superior Valuation, Momentum & Technical, Options & Structure while SYRE counters with relative strength in Growth & Margin. Fundamentally, MRNA trades at 23.0x Forward P/E with -80.8% operating margin (+29.2% YoY revenue) versus SYRE at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, MRNA sits in CONSOLIDATION (30th %ile IV; Dealer Gamma Walls on Pro) against SYRE sits in UNCLASSIFIED (10th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | MRNA | SYRE | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $93.6B | $9.8B | Larger Scale | MRNA |
| Trailing P/E Ratio Valuation | 23.0x | N/M | Lower Multiple | MRNA |
| Forward P/E Ratio Valuation | 23.0x | N/M | Lower Multiple | MRNA |
| Revenue Growth (YoY) Growth | +29.2% | +0.0% | Higher Growth | MRNA |
| Operating Margin (TTM) Profitability | -80.8% | 0.0% | Higher Margin | SYRE |
| Net Profit Margin Profitability | -110.5% | 0.0% | Higher Margin | SYRE |
| Return on Equity (ROE) Capital Efficiency | -34.5% | -35.0% | Higher ROE | MRNA |
| 52-Week Range Position Momentum | 75% ($22โ$281) | 88% ($22โ$111) | Stronger Trend | SYRE |
| Beta / 30D Volatility Risk Regime | 2.35ฮฒ ยท 101% Vol | 1.75ฮฒ ยท 59% Vol | Lower Realized Risk | SYRE |
| Unified Institutional Score Composite Signal | 46.8 / 100 (HOLD) | 44.4 / 100 (HOLD) | Higher Composite | MRNA |